medigraphic.com
Colegio de Medicina Interna de México.

2015, Number 4

<< Back Next >>

Med Int Mex 2015; 31 (4)

Cerebrovascular disease at Hospital Angeles Pedregal: cardiovascular risk factors and hospital prognosis

Aisa-Álvarez A, Cabrera-Jardines R, González-Patiño A, Palma-Carbajal R, Díaz-Greene E, Rodríguez-Weber F

Language: Spanish
References: 23
Page: 363-373
PDF size: 451.32 Kb.


ABSTRACT

Background: Nowadays, cerebrovascular disease (CVD) is a serious health problem, being the second cause of death in the world and third cause of disability.
Patients and method: An original, clinical-epidemiological, retrospective, descriptive, observational and comparative study, done at a private hospital south of Mexico City, was made including consecutive adult patients, both male and female with diagnostic records of CVD from the clinical file that were confirmed by neurological image methods.
Results: We registered 203 cases of CVD, excluding 10 patients in which the evaluation could not be completed. Ischemic arterial CVD presented in 149 patients (77%), hemorrhagic in 36 patients (19%) and cerebrovenous thrombosis (CVT) in 8 patients (4%). Patients with arterial CVD, both ischemic and hemorrhagic, were associated with higher scores when checked in using Framingham scale compared with CVT (≥3 vs ≤2, OR 41 IC95% 4.47-369, p=0.0000). Regarding to the hospital prognosis, patients with a NIHSS score at entering of 0-5 points were associated to a lower hospital mortality compared with the other patients with ≥6 points (OR 10.94, IC95% 1.34-89.38, p=0.0113).
Conclusions: The most frequent cause of CVD was ischemic; the most frequent pathophysiologic mechanism was cardioembolic. Cerebrovenous thrombosis affected women with low scores according Framingham scale. Patients with scores of NIHSS ≥6 have worst neurological outcome, and those who present hemorrhagic CVD obtain higher scores.


REFERENCES

  1. Krishnamurthi RV. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 2013.

  2. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 2014;129:e28.

  3. Brea A, Laclaustra M, et al. Epidemiología de la enfermedad vascular cerebral en España. Clin Invest Arterioscl 2013;25:211-217.

  4. Sacco RL. Risk factors, outcomes and stroke subtypes for ischemic stroke. Neurology 1997;49(Suppl 4):S39-S44.

  5. Sacco RL, et al. American Heart Association Prevention Conference, IV: prevention and rehabilitation of stroke. Risk factors. Stroke 1997;28:1507-1517.

  6. Cantú-Brito C. The Premier Study. Int J Stroke 2011;90-94.

  7. Agnelli G, Verso M. Epidemiology of cerebral vein and sinus thrombosis. Front Neurol Neurosci 2008;23:16-22.

  8. Gunther G, Arauz A. Trombosis venosa cerebral: aspectos actuales del diagnóstico y tratamiento. Neurología 2011;26:488-498.

  9. Ferro JM et ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004;35:664-670.

  10. Cantú C, Barinagarrementería F. Cerebral venous thrombosis associated with pregnancy and puerperium. A review of 67 cases. Stroke 1993;24:1880-1884.

  11. Tall AR. Plasma high-density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest 1990;86:379.

  12. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001;104:2376.

  13. Cantu C, Arauz A, Ruiz-Sandoval JL, Barinagarrementeria F, et al. Clinical outcome and stroke types in Hispanic mestizos. Presented at: Joint World Congress of Stroke; October 26-29, 2006; Cape Town, South Africa.

  14. Saposnik G. Diagnosis and management of cerebral venous thrombosis. Stroke 2011;42:1158-1192.

  15. Canhao P, Ferro JM, Lindgren AG, Bousser MG, Stam J, Barinagarrementeria F, ISCVT Investigators. Causes and predictors of death in cerebral venous thrombosis. Stroke 2005;36:1720-1725.

  16. Weimar C, König IR, Kraywinkel K, et al. Age and National Institutes of Health Stroke Scale Score within 6 hours after onset are accurate predictors of outcome after cerebral ischemia: development and external validation of prognostic models. Stroke 2004;35:158.

  17. Adams HP Jr, Davis PH, Leira EC, et al. Baseline NIH stroke scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999;53:126.

  18. Frankel MR, Morgenstern LB, Kwiatkowski T, et al. Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial. Neurology 2000;55:952.

  19. Ilercil A, Meisner JS, Vijayaraman P, et al. Clinical significance of fossa ovalis membrane aneurysm in adults with cardioembolic cerebral ischemia. Am J Cardiol 1997;80:96.

  20. Serena J, Marti-Fàbregas J, Santamarina E, et al. Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study. Stroke 2008;39:3131.

  21. Homma S, Sacco RL, Di Tullio MR, et al. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002;105:2625.

  22. Kent DM, Ruthazer R, Weimar C, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology 2013;81:619.

  23. González Patiño MA, Amador Mena JE, Rodriguez Weber FL. Foramen oval permeable asociado a enfermedad vascular cerebral de tipo isquémico; controversia en su tratamiento. Experiencia en el Hospital Ángeles Pedregal. Med Int Méx 2014;30:511-519.




2020     |     www.medigraphic.com